October 05, 2010 04:00 ET

IDBS Announces Agreement With Genomic Health to Help Streamline Development of Oncology Diagnostic Tools

IDBS Solutions Will Help Manage the Deluge of Genomic Data and Speed Analysis

GUILDFORD, UK and BURLINGTON, MA--(Marketwire - October 5, 2010) -  IDBS, the leading worldwide provider of research data management and analytics solutions to R&D and healthcare organizations, today announced that Genomic Health, Inc, a molecular diagnostics company focused on the global development and commercialization of genomic-based clinical laboratory services for cancer, has selected IDBS to provide the tools for its new clinical research data management and decision capture platform.

Genomic Health provides two clinically validated assays in the areas of breast cancer and colon cancer. These tests provide individualized tumor information that enable physicians and patients to make personalized treatment decisions, for example, to determine whether chemotherapy would be effective in early-stage breast cancer. Genomic Health uses a combination of gene expression technologies to build sensitive and quantitative gene expression profiles as the foundation for new oncology diagnostics. With increasing volumes of data being generated, the IDBS solutions will help Genomic Health capture genomic data from these multiple platforms and enable researchers to query the data across multiple experiments.

In addition, these tools will help Genomic Health's scientists obtain easy access to the data they need to run experiments and will ensure that all the intellectual property generated is effectively captured at the point of invention. Data analysis and annotation of resulting biomarkers can be automated using flexible and powerful InforSense workflows that ensure analysis is standardized and stored in E-WorkBook. 

"As we have expanded and refined our assays, the amount and heterogeneity of data generated has increased significantly, and the IDBS platform will help us manage the data today and as our organization continues to grow in the future," said Joel Robertson, Senior Manager of LIMS Software, Genomic Health.

"Both the E-WorkBook and InforSense Suites provide unique, valuable capabilities to the research community, and by combining aspects of the two suites, we have provided a revolutionary approach to managing and using critical biomarker data," said Neil Kipling, founder and CEO of IDBS. "We understand how our customers work and what they need to manage their data, and in doing so we provide the solutions that help advance their research."

About the IDBS Healthcare Unit
The IDBS Healthcare Unit is dedicated to the advancement of personalized medicines and improved patient outcomes through the delivery of advanced translational medicine and biomarker research informatics that bridge the worlds of clinical, molecular and image data. Our sophisticated data management and analytics solutions underpin improved disease understanding, more effective diagnosis and treatment selection. By delivering the enterprise infrastructures and managed services required for translational and biomarker studies, IDBS is revolutionizing research environments to enhance innovation, accelerate research and improve data and research quality. By working with leading organizations from bench to bedside, IDBS is enabling collaboration across the health science ecosystem.

About Genomic Health
Genomic Health, Inc. (NASDAQ: GHDX) is a molecular diagnostics company focused on the global development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004 Genomic Health launched the Oncotype DX® breast cancer test, which has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. In addition to the widely adopted Oncotype DX breast cancer test, Genomic Health launched its Oncotype DX colon cancer test in January 2010. As of June 30, 2010, more than 10,000 physicians in over 55 countries had ordered more than 160,000 Oncotype DX tests. For more information about the Oncotype DX breast and colon cancer tests, please visit

The company was founded in 2000 and is located in Redwood City, California. For more information please visit

About IDBS
IDBS is a unique, global supplier of innovative data management and first-in-class analytics solutions which increase efficiency reduce costs and improve the productivity of healthcare R&D organizations. Multinational pharmaceutical companies, major public-private healthcare partnerships, global leaders in academic study and high tech companies employ IDBS as a strategic supplier of scientific informatics and business process improvement solutions. IDBS is clearly differentiated by its unique combination of deep domain knowledge across the entire R&D sector: from the examination of the human genome at the scientist's bench, through the clinic, to translational medicine initiatives and pay-for-performance healthcare monitoring. IDBS solutions support the protection of intellectual property (IP) and the requirements for data quality and security demanded under Good Laboratory Practice (GLP), Good Manufacturing Practice (GMP) and HL7 (Health Level) standards. 

IDBS is a private company, founded in 1989 and headquartered in Guildford, UK. IDBS has worldwide consulting and support presence, with U.S. offices in California, New Jersey and Massachusetts, the EU, Australia and China. Find out more at

Contact Information

  • Media enquiries
    Danielle Guinebertiere
    Communications Director
    Tel: +1 908 429 2933
    Email: Email Contact